Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 16;12(1):101688. doi: 10.1016/j.jvsv.2023.09.002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 2 — Pooled proportions of patients with venous thromboembolism (VTE) recurrence after upper extremity vein thrombosis (UEVT). A, VTE recurrence rate for patients treated with direct oral anticoagulants (DOACs), low-molecular-weight heparin (LMWH), and vitamin K antagonists (VKAs) was 3%, 2%, and 4%, respectively. B, VTE recurrence rate for patients with cancer, patients without cancer, and patients with cancer and central venous catheter (CVC)-related thrombosis was 6%, 3%, and 5%, respectively. CI, Confidence interval.

Fig 2 — Pooled proportions of patients with venous thromboembolism (VTE) recurrence after upper extremity vein thrombosis (UEVT). A, VTE recurrence rate for patients treated with direct oral anticoagulants (DOACs), low-molecular-weight heparin (LMWH), and vitamin K antagonists (VKAs) was 3%, 2%, and 4%, respectively. B, VTE recurrence rate for patients with cancer, patients without cancer, and patients with cancer and central venous catheter (CVC)-related thrombosis was 6%, 3%, and 5%, respectively. CI, Confidence interval.